Stock has been increased to meet patient need, with up to 20,000 Australian patients potentially affected by shortages of other testosterone products

Besins Healthcare has issued an alert to reassure pharmacists that Testogel is unaffected by the TGA’s supply shortage notifications for two testosterone products:

  • Reandron 1000 testosterone undecanoate 1000mg in 4mL oily solution for injection vial (supply shortage from 1 October 2018 until 31 December 2018)
  • Primoteston Depot testosterone enantate 250mg/1mL injection syringe (supply shortage from 27 August 2018 until 31 March 2019).

Besins estimates that up to 20,000 Australian patients may be affected by these shortages.

It has confirmed full availability of the pump and sachet formulations of testosterone replacement therapy Testogel (1% transdermal testosterone gel), with Testogel stock levels increased to cover shortages of Reandron and Primoteston Depot in Australia.

“We want to assure clinicians concerned by supply shortages of injectable testosterone products that Testogel is unaffected by these shortages,” said Geoff Blundell, Managing Director of Besins Healthcare.

“We are pleased to confirm that wholesalers have access to ample stock of both the Testogel pump and sachet formulations to meet increased need during this period.

“We are working hard to ensure that doctors have access to therapeutic options for continuation of therapy for their patients with clinically significant testosterone deficiency,” he said.

The reassurance comes after a shortfall in global supply of Testogel sachets, following the withdrawal of competitor Axiron from the market in December last year.

This shortage lasted until August, when Besins announced stock levels had returned to normal and it was now “business as usual in Australia”.